InsidersTradesSigma
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the full record of transactions filed by Richman Eric I, Chairman & CEO. Director active across 2 companies, notably Gain Therapeutics, Inc.. Cumulatively, 7 reports have been published. Breakdown: 5 buys · 0 sell. Total volume traded: €57k. History available since 16 August 2021. The latest transaction was disclosed on 1 July 2024 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations
Eric I. Richman is a Director and Chief Executive Officer of Gain Therapeutics, Inc. and NeuBase Therapeutics, Inc. In these roles, he oversees the operations of the companies and is responsible for the overall strategy. Eric leverages his expertise to lead these companies towards growth and innovation initiatives.